#United States #Class Action #Los Angeles #Schall Law Firm #UroGen Pharma

UroGen Pharma Ltd. Class Action Lawsuit: What Investors Need to Know

On June 2, 2025, the Schall Law Firm, a prominent law firm specializing in shareholder rights and securities fraud litigation, announced the initiation of a class action lawsuit against UroGen Pharma Ltd. This lawsuit comes in the wake of significant allegations regarding UroGen's potential violations of the Securities Exchange Act of 1934. Investors who purchased UroGen's securities between July 27, 2023, and May 15, 2025, are called upon to join this effort before the upcoming deadline of July 28, 2025.

The Allegations

According to the complaint, UroGen Pharma made a series of false and misleading statements to the market regarding its clinical study of UGN-102, a treatment designed to address specific medical conditions. Notably, the ENVISION clinical study, which was intended to validate the effectiveness of UGN-102, failed to show conclusive evidence due to its lack of a concurrent control arm. This critical design flaw raised serious questions about the validity of the study's results and ultimately the effectiveness of UGN-102 itself.

Furthermore, the complaint alleges that UroGen disregarded multiple warnings from the FDA relating to the study's design. As this information came to light, it became apparent that UroGen's previous public statements had been misleading, leading investors to suffer significant financial damages when the truth was revealed.

Call to Action

The Schall Law Firm urges impacted shareholders to act swiftly to protect their rights and potential recoveries. If you experienced financial losses as a result of investing in UroGen during the specified class period, you have until July 28, 2025, to connect with the Schall Law Firm. Investors are encouraged to reach out to Brian Schall at the Schall Law Firm's Los Angeles office at 310-301-3335 or via email at [email protected] for a free consultation about their rights.

This press release is an important reminder that the class representing affected investors has yet to be certified legally. Until such certification occurs, those who do not take action will remain unrepresented in the ongoing legal proceedings. Therefore, participation in this class action is vital for anyone who wishes to reclaim losses incurred from UroGen’s alleged misconduct.

The Role of the Schall Law Firm

The Schall Law Firm stands out in the realm of securities class actions, advocating tirelessly for investors worldwide. With years of experience in shareholder rights litigation, the firm aims to hold corporations accountable for any unlawful actions that negatively affect their shareholders. Their mission is to recover losses suffered by investors and ensure that corporate transparency is upheld.

As this case unfolds, investors will likely gain clearer insights into the operations and ethics of UroGen Pharma Ltd. It’s essential for all affected shareholders to remain informed about developments related to this lawsuit and other pivotal factors that could impact the pharmaceutical company’s future.

Stay tuned for updates as the Schall Law Firm moves forward with this litigation, and don’t miss the opportunity to join this crucial class action to seek justice for your investments. This lawsuit not only aims to address alleged misdeeds but also emphasizes the importance of ethical practices within the corporate landscape.

To learn more, visit the Schall Law Firm’s website at www.schallfirm.com or contact them directly to discuss your specific situation and options. Remember, protecting your investments is paramount, and timely action is key to navigating such legal challenges effectively.